AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain (BTP). Its principal product candidate is Zalviso, an investigational pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. The company is also developing ARX-04, a Sufentanil Single-Dose NanoTab, which has completed Phase II clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as on the battlefield, in the emergency room, or in ambulatory care facilities. In addition, its product candidate pipeline consists of ARX-02, a Sufentanil NanoTab pain management system, which has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain (BTP); and ARX-03, a Sufentanil/Triazolam NanoTab, a Phase II clinical trials completed product designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, researches, develops, and commercializes products to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. The company's products include Oxecta tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed, a pseudoephedrine HCl tablet that is used as a nasal decongestant in various non-prescription and prescription cold, sinus, and allergy products. It has seven additional opioid products, including hydrocodone bitartrate/acetaminophen, methadone HCl, morphine sulfate, oxycodone HCl/acetaminophen, oxymorphone HCl, and tramadol HCl tablets utilizing Aversion technology in various stages of development. The company has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to manufacture and commercialize Oxecta products in the United States, Canada, and Mexico. Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois.
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, is focused on the discovery, development, and commercialization of first-in-class glaucoma therapies. Its lead product candidate, Rhopressa, is a once-daily triple-action eye drop, which demonstrated the ability to reduce intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension in a Phase 2b clinical trial. The company is conducting two Phase 3 registration trials in the U.S. to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol, as well as commencing a third safety-only Phase 3 registration trial of Rhopressa in Canada. It also develops once-daily quadruple-action Roclatan, a single drop combination of Rhopressa with latanoprost, which has completed a 28-day Phase 2b clinical trial. In addition, the company is taking preparatory steps for Phase 3 registration trials for Roclatan. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Bedminster, New Jersey.
Alexander & Baldwin, Inc., together with its subsidiaries, primarily provides real estate development and leasing services. The company operates through four segments: Real Estate Development and Sales, Real Estate Leasing, Natural Materials and Construction, and Agribusiness. The Real Estate Development and Sales segment is involved in the stewardship, planning, entitlement, development, and sale of land, and commercial and residential properties principally in Hawaii. The Real Estate Leasing segment owns, operates, and manages retail, office, and industrial properties in Hawaii and on the Mainland, as well as leases land in Hawaii. The Natural Materials and Construction segment mines, processes, and sells basalt aggregate; imports sand and aggregates for sale and use; imports and markets liquid asphalt; manufactures and markets asphaltic concrete; manufactures and supplies precast/prestressed concrete products; provides and markets various construction- and traffic-control-related products and services; and performs asphalt paving as prime contractor and subcontractor. The Agribusiness segment produces bulk raw sugar, specialty food grade sugars, and molasses; markets and distributes specialty food-grade sugars; provides general trucking services, and mobile equipment maintenance and repair services; leases agricultural land to third parties; and generates and sells electricity, as well as provides raw sugar marketing and transportation services. The company was formerly known as A & B II, Inc. and changed its name to Alexander & Baldwin, Inc. in June 2012. Alexander & Baldwin, Inc. was founded in 1870 and is headquartered in Honolulu, Hawaii.
Allied Nevada Gold Corp., a gold producer, is engaged in the mining, development, and exploration of properties in Nevada. The company's principal products comprise unrefined gold and silver bars. It operates the Hycroft Mine, an open pit heap leach operation located to the west of Winnemucca, Nevada. The company's properties also include Maverick Springs, Mountain View, Wildcat, and Pony Creek/Elliot Dome. In addition, it has approximately 73 other exploration properties. Allied Nevada Gold Corp. was incorporated in 2006 and is headquartered in Reno, Nevada.
Atlas Pipeline Partners, L.P. operates in the gathering and processing segments of the midstream natural gas industry. It operates through two segments, Gathering and Processing; and Transportation, Treating, and Other. The company provides natural gas gathering, processing, and treating services primarily in the Anadarko, Arkoma, and Permian basins located in the southwestern and mid-continent regions of the United States and in the Eagle Ford Shale play in south Texas; natural gas gathering services in the Appalachian basin in the northeastern region of the United States; and natural gas liquid transportation services in the southwestern region of the United States. It has interests in and operates 14 natural gas processing plants with aggregate capacity of approximately 1,500 million cubic feet per day located in Oklahoma and Texas; a gas treating facility in Oklahoma; and approximately 11,200 miles of active natural gas gathering systems in Oklahoma, Kansas, Tennessee, and Texas. The company's transportation and treating operations consist of 17 gas treating facilities that provide contract treating services to natural gas producers in Arkansas, Louisiana, Oklahoma, and Texas. Atlas Pipeline Partners, L.P. was founded in 1999 and is based in Pittsburgh, Pennsylvania.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. Its products under development include APD811, an agonist of the prostacyclin receptor, which has completed single- and multiple-ascending dose Phase I trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials. The company's products under development also comprise APD334, an agonist of the sphingosine 1-phosphate subtype 1 receptor for the treatment of conditions related to autoimmune diseases, which has completed Phase I single-ascending dose trial; and APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. It also manufactures drug products under a manufacturing services agreement for Siegfried AG. The company was founded in 1997 and is based in San Diego, California.
Baltic Trading Limited is engaged in shipping business in the drybulk industry spot market worldwide. The company operates a fleet of drybulk ships that transport iron ore, coal, grain, steel products, and other dry bulk cargoes. As of October 29, 2014, it owned four Capesize, four Supramax, one Ultramax, and five Handysize vessels with an aggregate carrying capacity of approximately 1,159,000 deadweight tons. The company charters its vessels to trading houses, including commodities traders, as well as producers and government-owned entities. Baltic Trading Limited was founded in 2009 and is based in New York, New York.
Chuy's Holdings, Inc., through its subsidiary, Chuy's Opco, Inc., owns and operates restaurants under the Chuy's name in Texas and 13 states in the southeastern and midwestern United States. The company's restaurants provide Mexican and Tex Mex inspired food. As of November 4, 2014, it owned and operated 59 full-service restaurants in 14 states. The company was founded in 1982 and is headquartered in Austin, Texas.
Chimera Investment Corporation operates as a real estate investment trust (REIT) in the United States. The company, through its subsidiaries, invests in residential mortgage-backed securities (RMBS), residential mortgage loans, commercial mortgage loans, real estate-related securities, and various other asset classes. Its targeted asset classes include non-agency RMBS, such as investment-grade and non-investment grade classes; agency RMBS; insured loans; and first or second lien loans secured by multifamily properties, mixed residential or other commercial properties, retail properties, office properties, and industrial properties. The company's other asset-backed (ABS) securities include commercial mortgage-backed securities, debt and equity tranches of collateralized debt obligations, and consumer and non-consumer ABS, as well as hedging instruments. The company has elected to be taxed as a REIT for federal income tax purposes and would not be subject to income tax, if it distributes at least 90% of its REIT taxable income to its share holders. Chimera Investment Corporation was founded in 2007 and is based in New York, New York.